Log In
BCIQ
Print this Print this
 

CA-327

  Manage Alerts
Collapse Summary General Information
Company Aurigene Discovery Technologies Ltd.
DescriptionOral small molecule antagonist of PD-L1 and T cell immunoglobulin and mucin domain 3 (TIM3; HAVCR2)
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) ; T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerCuris Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/21/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today